MX2020008415A - Metodos y composiciones que actuan de forma selectiva sobre linfocitos treg. - Google Patents
Metodos y composiciones que actuan de forma selectiva sobre linfocitos treg.Info
- Publication number
- MX2020008415A MX2020008415A MX2020008415A MX2020008415A MX2020008415A MX 2020008415 A MX2020008415 A MX 2020008415A MX 2020008415 A MX2020008415 A MX 2020008415A MX 2020008415 A MX2020008415 A MX 2020008415A MX 2020008415 A MX2020008415 A MX 2020008415A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- compositions
- treg cells
- act selectively
- treg lymphocytes
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- C12N5/0637—Immunosuppressive T lymphocytes, e.g. regulatory T cells or Treg
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
- G01N33/56977—HLA or MHC typing
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N1/00—Sampling; Preparing specimens for investigation
- G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
- G01N1/30—Staining; Impregnating ; Fixation; Dehydration; Multistep processes for preparing samples of tissue, cell or nucleic acid material and the like for analysis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Hematology (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Urology & Nephrology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862630084P | 2018-02-13 | 2018-02-13 | |
| PCT/US2019/017870 WO2019160970A1 (en) | 2018-02-13 | 2019-02-13 | Methods and compositions for targeting treg cells |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020008415A true MX2020008415A (es) | 2020-10-28 |
Family
ID=67619085
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020008415A MX2020008415A (es) | 2018-02-13 | 2019-02-13 | Metodos y composiciones que actuan de forma selectiva sobre linfocitos treg. |
| MX2025010847A MX2025010847A (es) | 2018-02-13 | 2020-08-11 | Metodos y composiciones que actuan de forma selectiva sobre linfocitos treg |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2025010847A MX2025010847A (es) | 2018-02-13 | 2020-08-11 | Metodos y composiciones que actuan de forma selectiva sobre linfocitos treg |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US12037410B2 (https=) |
| EP (1) | EP3752533A4 (https=) |
| JP (2) | JP7555270B2 (https=) |
| CN (1) | CN112041343B (https=) |
| AU (2) | AU2019221544B2 (https=) |
| BR (1) | BR112020016374A2 (https=) |
| CA (1) | CA3091181A1 (https=) |
| MX (2) | MX2020008415A (https=) |
| WO (1) | WO2019160970A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022246066A2 (en) * | 2021-05-19 | 2022-11-24 | Precision Biologics, Inc. | Methods and compositions for treating hematological malignancies |
| CN114010803B (zh) * | 2021-11-30 | 2023-04-07 | 广东省人民医院 | 一种检测活体肿瘤微环境中Treg细胞的多功能靶向分子探针及其应用 |
| AU2023272108A1 (en) * | 2022-05-19 | 2024-11-07 | Precision Biologics, Inc. | Methods for ablating myeloid derived suppressor cells using neo-201 antibody |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2010A (en) | 1841-03-18 | Machine foe | ||
| US4810781A (en) | 1987-01-15 | 1989-03-07 | The George Washington University | Methods of preparing epitopes of tumor associated antigens |
| USRE39760E1 (en) | 1988-03-31 | 2007-08-07 | International Bio-Immune Systems Inc. | Monoclonal antibodies against human colon carcinoma-associated antigens and uses therefor |
| US5688657A (en) | 1988-03-31 | 1997-11-18 | International Bio-Immune Systems, Inc. | Monoclonal antibodies against human colon carcinoma-associated antigens and uses therefor |
| EP1320551A4 (en) | 2000-09-01 | 2006-12-20 | Internat Bioimmune Systems Inc | IDENTIFICATION AND DEVELOPMENT OF SPECIFIC MONOCLONAL ANTIBODIES AGAINST SQUAFTEPITHELIC CARCINOMA |
| JP2004537976A (ja) | 2001-03-15 | 2004-12-24 | インターナショナル バイオイムン システムズ，インコーポレーテッド | 膵癌のモノクローナル抗体治療 |
| CA2604238C (en) | 2005-04-15 | 2015-07-07 | Neogenix Oncology, Inc. | Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers |
| WO2008103905A2 (en) * | 2007-02-23 | 2008-08-28 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Antibodies that specifically bind irta and methods of use |
| CA2700197C (en) | 2007-11-08 | 2020-09-08 | Neogenix Oncology, Inc. | Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers |
| US8277804B2 (en) * | 2008-05-21 | 2012-10-02 | Alderbio Holdings Llc | Antagonists of IL-6 to prevent or treat thrombosis |
| US20120064100A1 (en) | 2009-03-18 | 2012-03-15 | Simon Barry | Biomarkers and uses thereof |
| WO2011139738A2 (en) * | 2010-04-28 | 2011-11-10 | Tenx Biopharma, Inc. | Therapies using zanolimumab to enhance the immune response |
| US20130189268A1 (en) | 2010-06-22 | 2013-07-25 | Precision Biologics, Inc. | Colon and pancreas cancer specific antigens and antibodies |
| ES2719624T3 (es) | 2010-09-23 | 2019-07-11 | Prec Biologics Inc | Peptidomiméticos de cáncer de colon y de páncreas |
| WO2012075111A1 (en) * | 2010-11-30 | 2012-06-07 | Novartis Ag | Uses of anti-cd40 antibodies in combination therapy for b cell-related cancers |
| JP2013059295A (ja) * | 2011-09-14 | 2013-04-04 | Nagoya City Univ | ｓｉＲＮＡ、抗原提示細胞、制御性Ｔ細胞及び治療薬 |
| CN105188749B (zh) * | 2012-12-21 | 2017-12-19 | 西雅图基因公司 | 抗ntb‑a抗体及相关组合物和方法 |
| CA2896723C (en) | 2012-12-28 | 2024-02-13 | Precision Biologics, Inc. | Humanized monoclonal antibodies and methods of use for the diagnosis and treatment of colon and pancreas cancer |
| WO2014163684A1 (en) * | 2013-04-03 | 2014-10-09 | Ibc Pharmaceuticals, Inc. | Combination therapy for inducing immune response to disease |
| AU2014319921A1 (en) * | 2013-09-11 | 2016-03-17 | Compugen Ltd. | Anti-VSTM5 antibodies and the use thereof in therapy and diagnosis |
| PE20171790A1 (es) * | 2015-03-23 | 2017-12-28 | Bayer Pharma AG | Anticuerpos anti-ceacam6 y sus usos |
| US11279768B1 (en) * | 2015-04-03 | 2022-03-22 | Precision Biologics, Inc. | Anti-cancer antibodies, combination therapies, and uses thereof |
| EP3295171A1 (en) * | 2015-05-12 | 2018-03-21 | INSERM - Institut National de la Santé et de la Recherche Médicale | Methods and kits for labeling, detection and isolation of foxp3+ regulatory t cells, isolated population of foxp3+ regulatory t cells thus obtained and uses thereof |
| KR20190017735A (ko) * | 2016-04-07 | 2019-02-20 | 캔써 리서치 테크놀로지 리미티드 | 종양 특이적 세포 고갈을 위한 항 cd25 fc 감마 수용체 이중특이적 항체 |
| WO2018218230A1 (en) * | 2017-05-26 | 2018-11-29 | Etubics Corporation | Combination immunotherapies comprising il-15 superagonists |
| WO2019090134A1 (en) * | 2017-11-03 | 2019-05-09 | Precision Biologics, Inc. | Monoclonal antibody neo-201 for the treatment of human carcinomas |
| WO2020018425A1 (en) * | 2018-07-16 | 2020-01-23 | Nantcell, Inc. | Antibody-dependent cell-mediated toxicity mediated by alt-803 and neo-201 |
-
2019
- 2019-02-13 AU AU2019221544A patent/AU2019221544B2/en active Active
- 2019-02-13 JP JP2020564822A patent/JP7555270B2/ja active Active
- 2019-02-13 BR BR112020016374-0A patent/BR112020016374A2/pt unknown
- 2019-02-13 CN CN201980013096.6A patent/CN112041343B/zh active Active
- 2019-02-13 US US16/969,268 patent/US12037410B2/en active Active
- 2019-02-13 WO PCT/US2019/017870 patent/WO2019160970A1/en not_active Ceased
- 2019-02-13 MX MX2020008415A patent/MX2020008415A/es unknown
- 2019-02-13 EP EP19754490.1A patent/EP3752533A4/en active Pending
- 2019-02-13 CA CA3091181A patent/CA3091181A1/en active Pending
-
2020
- 2020-08-11 MX MX2025010847A patent/MX2025010847A/es unknown
-
2024
- 2024-06-07 US US18/737,186 patent/US20240400714A1/en active Pending
- 2024-09-10 JP JP2024155435A patent/JP2024177188A/ja active Pending
-
2025
- 2025-10-07 AU AU2025248631A patent/AU2025248631A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2019221544B2 (en) | 2025-07-10 |
| AU2025248631A1 (en) | 2025-10-30 |
| WO2019160970A1 (en) | 2019-08-22 |
| US20210002383A1 (en) | 2021-01-07 |
| CN112041343B (zh) | 2024-08-30 |
| AU2019221544A1 (en) | 2020-10-01 |
| MX2025010847A (es) | 2025-10-01 |
| JP2024177188A (ja) | 2024-12-19 |
| BR112020016374A2 (pt) | 2020-12-15 |
| JP7555270B2 (ja) | 2024-09-24 |
| EP3752533A4 (en) | 2021-05-05 |
| US12037410B2 (en) | 2024-07-16 |
| CA3091181A1 (en) | 2019-08-22 |
| US20240400714A1 (en) | 2024-12-05 |
| JP2021512965A (ja) | 2021-05-20 |
| CN112041343A (zh) | 2020-12-04 |
| EP3752533A1 (en) | 2020-12-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CR20200653A (es) | Anticuerpos que se dirigen al gp120 de vih y métodos de uso | |
| DOP2019000180A (es) | INHIBIDORES DE TGFß1 ISOFORMA-ESPECÍFICOS CONTEXTO-PERMISIVOS Y USO DE LOS MISMOS | |
| MX2020010412A (es) | Inhibidores de tirosina quinasa de bruton. | |
| PH12019501010A1 (en) | Arginase inhibitor combination therapies | |
| MX2020005477A (es) | Inmunoterapias con el uso de células efectoras potenciadas derivadas de ipsc. | |
| MX2020005701A (es) | Células efectoras inmunitarias potenciadas y usos de las mismas. | |
| EA201690618A1 (ru) | Ингибиторы тирозинкиназы брутона | |
| CL2021001432A1 (es) | Terapia de combinación de radioinmunoconjugados con inhibidores de daños y reparaciones del adn | |
| MX2017007537A (es) | Anticuerpos anti-pd-1 y sus metodos de uso. | |
| CL2017001920A1 (es) | Anticuerpos humanos contra glicoproteína del virus ébola | |
| NI201500067A (es) | Compuestos de pirrolopirimidina como inhibidores de quinasa | |
| BR112015013123A2 (pt) | inibidores de beta-lactamase | |
| MX381718B (es) | Agentes biologicos y su uso en plantas. | |
| BR112016000561A8 (pt) | compostos terapeuticamente ativos e seus métodos de uso | |
| CL2015002941A1 (es) | Usos terapéuticos de empaglifozina | |
| CL2016001231A1 (es) | Compuestos de inhibidor de autotaxina | |
| MX2009010066A (es) | Composiciones y metodos para la ablacion especifica de la evasion mutacional de terapias especificas para cancer. | |
| MX388981B (es) | Inhibidores de enzima 1 dependiente de inositol (ire-1alfa). | |
| BR112015020466A8 (pt) | inibidores de cdc7, seus usos, e composição farmacêutica | |
| EA201591501A1 (ru) | Терапевтические средства на основе csf-1 | |
| BR112016002287A2 (pt) | compostos terapeuticamente ativos e seus métodos de uso | |
| MX2016011132A (es) | Métodos para tratar una infección cutánea mediante la administración de un antagonista de il-4r. | |
| MX379312B (es) | Anticuerpos especificos para fcrn. | |
| MX2020008415A (es) | Metodos y composiciones que actuan de forma selectiva sobre linfocitos treg. | |
| BR112016004358A8 (pt) | combinação farmacêutica de um inibidor de alk e um inibidor de cdk para tratamento de doenças proliferativas de célula, composição farmacêutica, seus usos, e kit |